Products for Research Use Only
RegisterLogin

ORIC-944

CAT: 0013-GTR19234849-02Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19234849-02Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ORIC-944 is a potent, orally bioavailable, and selective PRC2 inhibitor designed for prostate cancer research. It demonstrates antitumor activity in both cellular assays and in vivo models, making it a valuable tool for investigating epigenetic mechanisms in oncology.
CAS Number
2369769-29-7
Product Name Alternative
ORIC944
Field of Research
Epigenetics & Chromatin
Purity
98.08% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7.23 mM) ; DMSO:80 mg/mL (175.24 mM)
Smiles
N#CC=1N=C2C (=CN=C (NCC=3C (F) =CC=C4OCCC43) N2C1) C5=CC=C (C=C5C) CN (C) C
Molecular Formula
C26H25FN6O
Molecular Weight
456.52
Storage Conditions
-20°C
Notes
For research use only.

Chemical Information

8-(4-((Dimethylamino)methyl)-2-methylphenyl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,2-c]pyrimidine-2-carbonitrile

Rinzimetostat is an orally bioavailable allosteric inhibitor of polycomb repressive complex 2 (PRC2), with potential antineoplastic activity. Upon oral administration, rinzimetostat targets and binds to the regulatory embryonic ectoderm development (EED) subunit of PRC2. This prevents the methyltransferase activity of PRC2, spefifically the methylation of histone 3 at lysine27 (H3K27). This depletes H3K27 trimethylation (H3K27me3) and modulates the expression of target genes. This may inhibit tumor cell proliferation. PRC2 is dysregulated in a variety of cancer cell types and is associated with poor prognosis. It is responsible for the methylation of H3K27 leading to transcriptional silencing. EED is essential for the histone methyltransferase activity of PRC2.

CAS Number2369769-29-7
PubChem CID155788096
IUPAC Name8-[4-[(dimethylamino)methyl]-2-methylphenyl]-5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]imidazo[1,2-c]pyrimidine-2-carbonitrile
Molecular FormulaC26H25FN6O
Molecular Weight456.5
XLogP4.9
Topological Polar Surface Area78.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count6
Heavy Atom Count34
Formal Charge0
Complexity744
SMILES
CC1=C(C=CC(=C1)CN(C)C)C2=CN=C(N3C2=NC(=C3)C#N)NCC4=C(C=CC5=C4CCO5)F
InChI
InChI=1S/C26H25FN6O/c1-16-10-17(14-32(2)3)4-5-19(16)22-13-30-26(33-15-18(11-28)31-25(22)33)29-12-21-20-8-9-34-24(20)7-6-23(21)27/h4-7,10,13,15H,8-9,12,14H2,1-3H3,(H,29,30)
InChIKey
FLCIOLFIDGTRCI-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of 8-(4-((Dimethylamino)methyl)-2-methylphenyl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,2-c]pyrimidine-2-carbonitrile
CAS: 2369769-29-7
CID: 155788096
Formula: C26H25FN6O
MW: 456.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight456.5
XLogP34.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count6
Exact Mass456.20738760
Monoisotopic Mass456.20738760
Topological Polar Surface Area78.5 Ų
Heavy Atom Count34
Formal Charge0
Complexity744
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
GTR19234850-01ORIC-533
GTR19203545-01ORIC-101
GTR19173182-01AVN-944
GTR19320700-01Hsa-miR-944 miRNA Mimic
GTR19320704-01Hsa-miR-944 miRNA Agomir
GTR19320703-01Hsa-miR-944 miRNA Antagomir
GTR19320701-01Hsa-miR-944 miRNA Inhibitor
GTR19261397-01ORI-TRN-002

Alternative Products

CatalogName
T87073-01ORIC-944
T89268-01ORIC-944 TFA
BA5995-1ORIC-101
T87072-01ORIC-533
MBS130678-01AVN-944(VX-944)
200390AVN-944
6367/10Z 944

Popular Products